Interleukin-2 as therapy for hiv disease

Eddys Disla, Billi Goldberg, Giuseppe Landonio, Claudia Baiocchi, Massimo Ferrari, H. Clifford Lane, Joseph A. Kovacs

Research output: Contribution to journalLetterpeer-review

Abstract

To the Editor: The article by Kovacs et al. on interleukin-2 therapy in patients with human immunodeficiency virus (HIV) infection (March 2 issue)1 highlights the dilemma that this disease poses: how to get rid of a virus whose replication is enhanced by activation of the immune system. The increase in the HIV RNA level after an infusion of interleukin-2 was most consistent in patients with CD4 counts of 200 or fewer cells per cubic millimeter. In this group, interleukin-2 was associated with “few immunologic improvements, and substantial toxic effects,” but increased levels of HIV RNA were also observed in patients.

Original languageEnglish
Pages (from-to)192-193
Number of pages2
JournalNew England Journal of Medicine
Volume333
Issue number3
DOIs
StatePublished - 20 Jul 1995
Externally publishedYes

Fingerprint

Dive into the research topics of 'Interleukin-2 as therapy for hiv disease'. Together they form a unique fingerprint.

Cite this